dMMR/MSI-H is more commonly observed in the early stages of tumors, which may be due to the high tumor mutational burden (TMB) in early-stage colorectal cancer generating abundant neoantigens, activating CD8+ T cell infiltration, forming an immunogenic microenvironment that inhibits tumor progression. The gene discussed is CD8A; the disease is neoplasm.